Part 1–Conceptual Framework
Chapter 1–Conceptual Framework for Prescribing Psychotropic
Part 2–Practical Guidance
Chapter 3–Prescribing Medications: Getting Started
Part 3–Group 1 Medications for Specific Diagnoses: ADHD, Anxiety, and Depression
Chapter 4–Group 1 Medications for Attention-Deficit/Hyperactivity Disorder
Chapter 5–Group 1 Medications for Anxiety and Depression
Part 4–Group 2 (FDA-Approved Antipsychotics and Mood Stabilizers) and Group 3 (All Other) Medications
Chapter 6–Group 2 Medications: Antipsychotics and Mood Stabilizer
Chapter 7–Group 3 Medications
Part 5–Advanced Topics
Chapter 8–What to Do When Treatment Is Not Successful
Completely updated and revised, the second edition provides primary care physicians with practice-tested, condition-specific treatment recommendations for various childhood mental disorders. Obtain clear guidance on dosing, monitoring, and potential adverse reactions of psychotropic medications for treatment of common psychiatric disorders and mental health or behavioral problems in children and adolescents.
This simple, systematic approach defines discrete levels of psychotropics and spells out group-specific roles and responsibilities in accord with AAP policies. Plus, an included digital tool offers instant access to authoritative answers on specific conditions and medications.
• Conceptual framework for prescribing psychotropic drugs
• Medications for specific diagnoses: ADHD, Anxiety, and Depression
• US Food and Drug Administration-Approved antipsychotics and mood stabilizers and all other medications
• What to do when treatment is unsuccessful
• Mark A. Riddle, M.D. is Professor of Psychiatry and Pediatrics and former Director of the Division of Child and Adolescent Psychiatry at the Johns Hopkins University School of Medicine. His research, teaching and clinical practice focuses on pediatric psychopharmacology, particularly the efficacy and safety of psychotropic medications in children and adolescents. Dr. Riddle serves as a member of the National Institute of Child Health and Human Development-sponsored Data and Safety Monitoring Board for the Best Pharmaceuticals for Children Act. His clinical research and publications include pivotal studies of all of the major groups of medications prescribed to treat psychiatric disorders in children and adolescents.
• Jane Meschan Foy, MD, FAAP, has spent more than 35 years in pediatric primary care, public health, administration, and medical teaching. Her special interests include mental health services in pediatric primary care and school settings, access to health care for underserved populations, primary care of children with special health care needs, and residency training in mental health, community pediatrics, and advocacy. Dr Foy received her bachelor of arts from Wellesley College and her doctorate of medicine from University of North Carolina at Chapel Hill School of Medicine. She completed her residency training in pediatrics at University of North Carolina hospitals. She has held several academic positions and is currently professor of pediatrics at Wake Forest University School of Medicine and medical director of the Northwest Community Care Network (a regional network of North Carolina Medicaid providers). She is active in the American Academy of Pediatrics (AAP), having served as chair of the AAP Task Force on Mental Health from 2004 to 2010 and currently serving as past chair of the AAP National Committee on Psychosocial Aspects of Child and Family Health; member of the AAP Mental Health Leadership Work Group, and member of the AAP Board of Directors. Roles in other organizations have included the presidency of the North Carolina Pediatric Society (North Carolina Chapter of the AAP) from 1998 to 2000 and cofounder and director of the School Health Alliance for Forsyth County from 1999 to 2011.